ACS Medicinal Chemistry Letters
Letter
(18) Ball, S.; Li, C.; Li, P. K.; Lin, J. The small molecule, LLL12,
inhibits STAT3 phosphorylation and induces apoptosis in medullo-
blastoma and glioblastoma cells. PLoS One 2011, 6, e18820.
(19) Liu, A.; Liu, Y.; Li, P. K.; Li, C.; Lin, J. LLL12 inhibits
endogenous and exogenous interleukin-6-induced STAT3 phosphor-
ylation in human pancreatic cancer cells. Anticancer Res. 2011, 31,
2029−2035.
AUTHOR INFORMATION
■
Corresponding Authors
Notes
The authors declare no competing financial interest.
(20) Bhasin, D.; Chettiar, S. N.; Etter, J. P.; Mok, M.; Li, P.
Anticancer activity and SAR studies of substituted 1, 4-naphthoqui-
nones. Bioorg. Med. Chem. 2013, 21, 4662−4669.
ABBREVIATIONS
■
(21) Schust, J.; Sperl, B.; Hollis, A.; Mayer, T. U.; Berg, T. Stattic: a
small-molecule inhibitor of STAT3 activation and dimerization. Chem.
Biol. 2006, 13, 1235−1242.
(22) Chen, H.; Yang, Z.; Ding, C.; Xiong, A.; Wild, C.; Wang, L.; Ye,
N.; Cai, G.; Flores, R. M.; Ding, Y.; Shen, Q.; Zhou, J. Discovery of
potent anticancer agent HJC0416, an orally bioavailablesmall molecule
inhibitor of signal transducer and activator oftranscription 3 (STAT3).
Eur. J. Med. Chem. 2014, 82, 195−203.
(23) Hou, S.; Yi, Y. W.; Kang, H. J.; Zhang, L.; Kim, H.; Kong, Y.;
Liu, Y.; Wang, K.; Kong, H.; Grindrod, S.; Bae, I.; Brown, L. M. Novel
Carbazole Inhibits Phospho-STAT3 through Induction of Protein−
Tyrosine Phosphatase PTPN6. J. Med. Chem. 2014, 57, 6342−6353.
(24) Ren, X.; Duan, L.; He, Q.; Zhang, Z.; Zhou, Y.; Wu, D.; Pan, J.;
Pei, D.; Ding, K. Identification of niclosamide as a new small-molecule
inhibitor of the STAT3 signaling pathway. ACS Med. Chem. Lett. 2010,
1, 454−459.
(25) Chen, H.; Yang, Z.; Ding, C.; Chu, L.; Zhang, Y.; Terry, K.; Liu,
H.; Shen, Q.; Zhou, J. Discovery of O-Alkylamino-Tethered
Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer
Agents. ACS Med. Chem. Lett. 2013, 4, 180−185.
(26) Siddiquee, K.; Zhang, S.; Guida, W. C.; Blaskovich, M. A.;
Greedy, B.; Lawrence, H. R.; Yip, M. L.; Jove, R.; McLaughlin, M. M.;
Lawrence, N. J.; Sebti, S. M.; Turkson, J. Selective chemical probe
inhibitor of Stat3, identified through structure-based virtual screening,
induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104,
7391−7396.
(27) Haftchenary, S.; Luchman, H. A.; Jouk, A. O.; Veloso, A. J.;
Page, B. D. G.; Cheng, X. R.; Dawson, S. S.; Grinshtein, N.; Shahani,
V. M.; Kerman, K.; Kaplan, D. R.; Griffin, C.; Aman, A. M.; Al-awar,
R.; Weiss, S.; Gunning, P. T. Potent Targeting of the STAT3 Protein
in Brain Cancer Stem Cells: A Promising Route for Treating
Glioblastoma. ACS Med. Chem. Lett. 2013, 4, 1102−1107.
(28) Liu, X.; Guo, W.; Wu, S.; Wang, L.; Wang, J.; Dai, B.; Kim, E. S.;
Heymach, J. V.; Wang, M.; Girard, L.; Minna, J.; Roth, J. A.; Swisher,
S. G.; Fang, B. Antitumor activity of a novel STAT3 inhibitor and
redox modulator in non-small cell lung cancer cells. Biochem.
Pharmacol. 2012, 83, 1456−1464.
(29) Guo, W.; Wu, S.; Wang, L.; Wei, X.; Liu, X.; Wang, J.; Lu, Z.;
Hollingshead, M.; Fang, B. Antitumor activity of a novel oncrasin
analogue is mediated by JNK activation and STAT3 inhibition. PLoS
One 2011, 6, e28487.
(30) Yu, W.; Xiao, H.; Lin, J.; Li, C. Discovery of novel STAT3 small
molecule inhibitors via in silico site-directed fragment-based drug
design. J. Med. Chem. 2013, 56, 4402−4412.
DCM, dichloromethane; DCC, dicyclohexylcarbodiimide;
DMAP, 4-dimethylaminopyridine; TEA, triethylamine; RT,
room temperature; SD, standard deviation; MTT, 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide;
DCFH-DA, 2′,7′-dichlorofluorescin diacetate
REFERENCES
■
(1) Bromberg, J. F.; Wrzeszczynska, M. H.; Devgan, G.; Zhao, Y.;
Pestell, R. G.; Albanese, C.; Darnell, J. E. Stat3 as an oncogene. Cell
1999, 98, 295−303.
(2) Bromberg, J.; Darnell, J. E. The role of STATs in transcriptional
control and their impact on cellular function. Oncogene 2000, 19,
2468−2473.
(3) Turkson, J.; Jove, R. STAT proteins: novel molecular targets for
cancer drug discovery. Oncogene 2000, 19, 6613−6626.
(4) Hirano, T.; Ishihara, K.; Hibi, M. Roles of STAT3 in mediating
the cell growth, differentiation and survival signals relayed through the
IL-6 family of cytokine receptors. Oncogene 2000, 19, 2548−2556.
(5) Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest. 2002,
109, 1139−1142.
(6) Johnston, P. A.; Grandis, J. R. STAT3 signaling: anticancer
strategies and challenges. Mol. Interventions 2011, 11, 18.
(7) Yu, H.; Jove, R. The STATs of cancer-new molecular targets
come of age. Nat. Rev. Cancer 2004, 4, 97−105.
(8) Wei, L. H.; Kuo, M. L.; Chen, C. A.; Chou, C. H.; Lai, K. B.; Lee,
C. N.; Hsieh, C. Y. Interleukin-6 promotes cervical tumor growth by
VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003,
22, 1517−1527.
(9) Ahluwalia, A.; Busse, B. A.; Thiruvengadam, S. S.; Tarnawski, A.
S. Importins are critical for colorectal cancer (CRC) growth and are
novel biomarkers of CRC. Underlying mechanisms include:increased
nuclear transport of P-CREB and p-STAT3, VEGF gene promoter
activation and aberrant VEGF expression. Gastroenterology. 2011, 140,
S184.
(10) Page, B. D.; Ball, D. P.; Gunning, P. T. Signal transducer and
activator of transcription 3 inhibitors: A patent review. Expert Opin.
Ther. Pat. 2011, 21, 65−83.
(11) Debnath, B.; Xu, S.; Neamati, N. Small molecule inhibitors of
signal transducer and activator of transcription 3 (Stat3) protein. J.
Med. Chem. 2012, 55, 6645−6668.
(12) Deng, J.; Grande, F.; Neamati, N. Small molecule inhibitors of
Stat3 signaling pathway. Curr. Cancer Drug Targets 2007, 7, 91−107.
(13) Al Zaid Siddiquee, K.; Turkson, J. STAT3 as a target for
inducing apoptosis in solid and hematological tumors. Cell Res. 2008,
18, 254−267.
(14) Darnell, J. E. Transcription factors as targets for cancer therapy.
Nat. Rev. Cancer 2002, 2, 740−749.
(15) Darnell, J. E. Validating Stat3 in cancer therapy. Nat. Med. 2005,
11, 595−596.
(16) Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular-weight
compound discovered through virtual database screening inhibits Stat3
function in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102,
4700−4705.
(17) Lin, L.; Hutzen, B.; Li, P. K.; Ball, S.; Zuo, M.; DeAngelis, S.;
Foust, E.; Sobo, M.; Friedman, L.; Bhasin, D.; Cen, L.; Li, C.; Lin, J. A
novel small molecule, LLL12, inhibits STAT3 phosphorylation and
activities and exhibits potent growth-suppressive activity in human
cancer cells. Neoplasia. 2010, 12, 39−50.
(31) Li, H.; Liu, A.; Zhao, Z.; Xu, Y.; Lin, J.; Jou, D.; Li, C. Fragment-
based drug design and drug repositioning using multiple ligand
simultaneous docking (MLSD): identifying celecoxib and template
compounds as novel inhibitors of signal transducer and activator of
transcription 3 (STAT3). J. Med. Chem. 2011, 54, 5592−5596.
(32) Boengler, K.; Ungefug, E.; Heusch, G.; Schulz, R. The STAT3
inhibitor Stattic impairs cardiomyocyte mitochondrial function
through increased reactive oxygen species formation. Curr. Pharm.
Des. 2013, 19, 6890−6895.
(33) Alonso, M. M.; Asumendi, A.; Villar, J.; Gil, M. J.; Martınez-
Merino, V.; Encıo, I. J.; Migliaccio, M. New benzo(b)-
thiophenesulphonamide 1, 1-dioxide derivatives induce a reactive
oxygen species-mediated process of apoptosis in tumour cells.
Oncogene 2003, 22, 3759−3769.
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX